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Background: The formation of chromatin domains is an important step in lineage commitment. In human
hematopoietic stem and progenitor cells (HSPCs), G9a/GLP-dependent H3K9me2 chromatin territories form
de novo during lineage specification and are nucleated at punctate sites during lineage commitment. Here, we
examined the patterning of G9a/GLP-dependent H3K9me2 in HSPCs and the consequences for chromatin
structure.
Results: We profiled chromatin accessibility across the genome of HSPCs treated with either a small molecule
inhibitor of G9a/GLP or DMSO. We observed that chromatin accessibility is dramatically altered at the regions of
H3K9me2 nucleation. We have characterized the regions of H3K9me2 nucleation, with our analysis revealing that
H3K9me2 is nucleated in HSPCs at CpG islands (CGIs) and CGI-like sequences across the genome. Our analysis
furthermore revealed a bias of H3K9me2 nucleation towards regions with low rates of C- > T deamination, which
typically lack DNA methylation. Lastly, we examined the interaction of H3K9me2 and DNA methylation and
determined that chromatin accessibility changes upon loss of H3K9me2 are dependent on the presence of DNA
methylation.
Conclusions: These results indicate that H3K9me2 nucleation is established at specific sequences that have base
composition similar to CGIs. Our results furthermore indicate that H3K9me2 nucleation leads to local changes in
chromatin accessibility and that H3K9me2 and DNA methylation work synergistically to regulate chromatin
accessibility.
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G9a/EHMT2 and GLP/EHMT1 are conserved protein
lysine methyltransferases that play key roles in regulat-
ing gene expression and chromosome structure during
mammalian development through de novo mono- and
di-methylation of histone H3 lysine 9 (H3K9me1/2),
histone marks associated with transcriptional repression
[1-5]. During embryogenesis, large G9a/GLP-dependent
H3K9me2 chromatin territories arise that have been pro-
posed to reinforce lineage choice by determining higher
order chromatin structure [4].* Correspondence: dschones@coh.org; paddison@fhcrc.org
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unless otherwise stated.We recently observed that in adult human hematopoietic
stem and progenitor cells (HSPCs), H3K9me2 chromatin
territories are absent in primitive cells and are formed
de novo during lineage commitment [6]. In committed
HSPCs, G9a/GLP activity nucleates H3K9me2 marks
at CpG islands (CGIs) and other genomic sites, and
this mark then spreads to form larger domains during
differentiation [6]. A recently developed small molecule
inhibitor of G9a and GLP, UNC0638, inhibits the methyl-
transferase activity of both proteins by blocking substrate
access to the SET domains [7]. We have shown that treat-
ment of HSPCs with UNC0638 results in a genome-wide
loss of H3K9me2, a less dramatic reduction in H3K9me1
and no effect on H3K9me3 or the expression of G9a [6].
These results are consistent with previous studies showing
that loss of G9a leads to loss of H3K9me1/me2 [8,9]. Wel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a G9a/GLP small molecular inhibitor, better retain stem
cell-like phenotypes and function during in vitro expan-
sion and increased expression of lineage-affiliated genes
and certain gene clusters, suggestive of changes in regula-
tion of chromatin structure [6].
Primitive hematopoietic stem cells (HSCs) have been
hypothesized to have a more “open” chromatin structure
that might help maintain a multipotent state by, for
example, allowing transcriptional priming of lineage-
affiliated genes [10-12]. One possible interpretation
from our previous data is that G9a/GLP-H3K9me2
patterning helps restrict chromatin accessibility to reinforce
lineage commitment. To investigate this, we examined the
consequences of G9a/GLP-dependent H3K9me2 patterning
on chromatin structure in HSPCs using FAIRE-seq
(Formaldehyde Assisted Isolation of Regulatory Elements
Sequencing) [13] to map accessible chromatin in CD34+
HSPCs treated with UNC0638 or dimethyl sulfoxide
(DMSO) control (see Methods and Additional file 1:
Table S1). We furthermore investigated the sequence
features of sites of H3K9me2 nucleation. Our results
indicate that H3K9me2 is nucleated at CGI-like sites
across the genome, with a bias towards regions with
low rates of C- > T deamination. Our results further
demonstrate that H3K9me2 nucleation is associated
with loss of chromatin accessibility and that changes in
chromatin accessibility corresponding to loss of H3K9me2
are dependent on the presence of DNA methylation.
Results and discussion
Our previous results revealed that H3K9me2 patterning
progresses through distinct stages during HSC differ-
entiation. First, H3K9me2 marks appear low or absent
in HSC-enriched CD34+CD90+CD38loCD45RA– cells
[6]. Next, in CD34+ HSPCs (composed mainly of com-
mitted progenitors), a nucleation stage ensues in which
H3K9me2 marks appear at discrete loci across the
genome [6]. Finally, H3K9me2 marks spread across the
genome, presumably in cis from sites of nucleation, to
form characteristic patterns in mono-lineage cells such
as CD41+CD61+ committed megakaryocytes or CD3+
T-cells [6]. For our investigation into the relationship
between H3K9me2 patterning and chromatin accessibility,
we chose to examine HSPCs given they represent the
nucleation stage of H3K9me2 patterning. To do this we
performed chromatin accessibility profiling with FAIRE-
seq and integrated this data with H3K9me2 ChIP-seq and
DNA methylation data from the same cells (Figure 1A).
UNC0638 is highly effective at this stage in blocking
H3K9me2 nucleation, permitting analysis at sites of nucle-
ation in the absence of H3K9me2 marks. Visual examin-
ation of H3K9me2 and FAIRE tracks in CD34+ HSPCs
revealed mutual exclusivity in signals for H3K9me2 andchromatin accessibility (Figure 1B). Furthermore, closer
examination of the genomic profiles indicated that loss of
H3K9me2 upon UNC0638 treatment was associated with
increase in chromatin accessibility (Figure 1C). This trend
was supported by qPCR analysis for FAIRE and H3K9me2
ChIP as well (Additional file 2: Figure S1). These observa-
tions are consistent with H3K9me2 leading to chromatin
condensation and loss of H3K9me2 leading to an increase
in chromatin accessibility.
To examine this on a genome-wide scale, we identified
all sites of H3K9me2 nucleation (“peaks”) in CD34+
cells and counted the FAIRE reads in DMSO- and
UNC0638-treated cells. This analysis revealed increased
chromatin accessibility as the predominant behavior at
H3K9me2 sites upon treatment with UNC0638 (Figure 1D).
To evaluate these results in terms of the background level
of chromatin changes across the genome, we randomly
sampled sites from the genome and calculated the fold
change in FAIRE signal at these randomly chosen regions.
Compared to regions of H3K9me2 nucleation, ran-
domly sampled regions had significantly smaller changes
(P = 2.03577 × 10-250; Wilcoxon rank sum test) in chroma-
tin accessibility (Figure 1E). We further evaluated the
background changes in chromatin accessibility by sliding
1 kb windows in 50 bp increments across the genome and
calculating the fold change of FAIRE read density in
UNC0638-treated cells versus control cells. This analysis
revealed that changes in FAIRE-seq read densities upon
UNC0638 treatment were largely specific to H3K9me2
nucleation sites, indicating that changes in chromatin
structure are specific to sites of H3K9me2 nucleation (see
Additional file 3: Figure S2).
Our previous results indicated that a large percentage
of the H3K9me2 nucleation sites (~50%) were at CpG
islands [6], but it was unclear what the sequence basis of
the non-CGI sites was. In order to more extensively inves-
tigate the relationship between H3K9me2 peaks, CGIs,
and UNC0638-driven changes in chromatin structure, we
first reanalyzed overlap with nucleation sites and CGIs as
defined by the UCSC Genome Browser [14,15], which
classifies 28,691 CGIs throughout the genome. This ana-
lysis shows that 48% of nucleation sites overlap CGIs,
similar to our previous results. Further examination of the
sequence content for both CGI and non-CGI H3K9me2
sites revealed that non-CGI H3K9me2 sites had GC and
CpG content, similar to CGIs, but were not meeting the
thresholds of classical CGIs (Figure 2A,B) [14].
We next stratified CGIs based on whether they are
promoter associated or “orphan” sites, as defined by
Illingworth et al. [16] and analyzed UNC0638-driven
changes in chromatin. Of the CGIs in the human genome,
approximately half are associated with promoters and may
play roles in facilitating transcriptional regulation while
the other half are found in inter- and intragenic regions
Figure 1 H3K9me2 is associated with condensed chromatin and removal of H3K9me2 through UNC0638 reverses chromatin condensation.
(A) A flow diagram summarizing the study. See text for details. (B) Genome browser screen shot of the HOX locus on chromosome 7 indicating a
mutual exclusivity of H3K9me2 and chromatin accessibility as measured with FAIRE as well as an increase in chromatin accessibility upon
loss of H3K9me2 following UNC0638 treatment. (C) Closer look at the HOXA9 and HOXA10 reveals the relationship between H3K9me2 and
chromatin accessibility as measured by FAIRE. (D) Scatter plot of normalized FAIRE signals at all H3K9me2 sites in HSPCs for UNC0638- and
DMSO-treated samples reveals a general increase of chromatin accessibility at H3K9me2 sites upon UNC0638 treatment. (E) Fold change
(UNC0638/DMSO) for FAIRE signals at H3K9me2 sites as compared to randomly selected regions. Sites of H3K9me2 nucleation in HSPCs are
unique in their response to UNC0638.
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[17]. Analysis of FAIRE read counts across both promoter
and orphan CGIs indicates that both sets of CGIs display
similar behavior to all sites of H3K9me2 nucleation, with
dramatic increases in chromatin accessibility in response
to UNC0638 (Figure 2C).
The GC and CpG content of H3K9me2 nucleation
sites suggest that H3K9me2 is established in CD34+
HSPCs at CpG islands that do not necessarily meet
thresholds based on sequence content to be considered
CGIs. The initial characterization of CpG islands was
based on the experimental observation that there is an
enrichment of unmethylated CpG dinucleotides in the
mouse genome [18]. Recently, evolutionary analysis of
CGIs in primate genomes has been used to classify CGIs
in several evolutionary regimes: i) those with low ratesof C- > T deamination that are predicted to be mostly
unmethylated, ii) those that display rapid G/C gain that
are predicted to be constitutively methylated, and iii)
those under selection [19]. Examining the overlap of
CGIs belonging to these categories with the H3K9me2
nucleation sites revealed that H3K9me2 is preferentially
established at CGIs with low rates of C- > T deamination
(Figure 3A). We next investigated the effect that loss of
H3K9me2 had on chromatin accessibility for CGIs in
each group. Each group had an increase in chromatin
accessibility upon loss of H3K9me2 (see Additional file 4:
Figure S3). For ease of interpretation, we removed CGIs
under selection from analysis. Both CGIs with low rates of
C- > T deamination and those that rapidly gain G/C con-
tent had substantial increases in chromatin accessibility
upon loss of H3K9me2, with more dramatic changes for
Figure 2 H3K9me2 is nucleated at CpG-island-like regions across the genome. Measuring the (A) GC% and (B) CpG score at H3K9me2 peaks
overlapping and non-overlapping CGIs and comparing these to randomly chosen regions indicates that H3K9me2 peaks have GC content similar to
CGIs, even if they are not considered “classical” CGIs. (C) Scatter plot of FAIRE signals at RefSeq promoter and Orphan CGIs for UNC0638- and
DMSO-treated samples. A general increase in chromatin accessibility upon UNC0638 treatment is observed at both Promoter and Orphan CGIs.
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Examining the DNA methylation status of these regions
indicated that, as expected, the CGIs with low rates of
C- > T deamination were mostly unmethylated while
those CGIs with rapid G/C gain were mostly methylated
(Figure 3C).
Given these results, we next investigated the potential
role of DNA methylation on CGIs in response to UNC0638.
We stratified promoter-based CGIs into those that are
methylated and those that are unmethylated (Methods)
and examined the changes in chromatin accessibility for
both groups in response to UNC0638 treatment. The
biggest changes occurred at unmethylated CGIs (11,977
total), where UNC0638 dramatically increases chromatin
accessibility (Figure 4A,B). In contrast, methylated CGIs
(767 total) were more modestly affected, with UNC0638
treatment increasing the FAIRE signal roughly back to
background levels (Figure 4C,D). In our analysis, CGIs
had low chromatin accessibility regardless of methylation
status, consistent with these regions being marked with
H3K9me2 in HSPCs. Thus, H3K9me2 patterning is
critical for inducing chromatin structure observed at
unmethylated CGIs, which represent the majority of
CGIs, and to a lesser degree at methylated CGIs.Conclusions
In summary, we find that H3K9me2 patterning regu-
lates chromatin structure at promoter and orphan CGIs
and other sites of H3K9me2 nucleation, specifically
promoting “closed” chromatin states. These results sup-
port the notion that G9a/GLP-H3K9me2 participates in
global changes in chromatin structure in addition to
histone patterning during HSC lineage formation. How-
ever, the biological significance of this patterning re-
mains a question. One possibility is that H3K9me2
patterning helps reinforce chromatin states at sites of
transcription during lineage specification, which may
need to be reset in certain lineages and re-formed de
novo. To our knowledge, this is the first observation of
coordination between H3K9me2 patterning, promoter
and orphan CGIs, DNA methylation, and chromatin
structure.
Methods
Cell culture and treatment
Human CD34+ cells from healthy adults were purchased
from the Fred Hutchinson Cancer Research Center Cell
Processing Shared Resource, as described previously [6].
Unfractionated CD34+ cells were treated with 2 μM of
Figure 4 DNA methylation protects regions of reversal of chromatin condensation upon suppression of H3K9me2. (A) Aggregate plots
of FAIRE density at unmethylated promoter CGIs indicate that chromatin accessibility is completely reversed upon suppression of H3K9me2 for
unmethylated promoter CGIs. (B) Scatter plot of FAIRE signals at unmethylated promoter CGIs demonstrates that changes in chromatin
accessibility under UNC0638 treatment resemble changes at all H3K9me2 sites (Figure 1D). (C) Aggregate plots of FAIRE density at methylated
promoter CGIs reveals a mitigated increase in chromatin accessibility upon loss of H3K9me2 at methylated promoter CGIs. (D) Scatter plot of
FAIRE signals at methylated promoter CGIs confirms that methylated CGIs have less change in chromatin accessibility under UNC0638 treatment.
Figure 3 H3K9me2 nucleation and effect on chromatin accessibility is biased towards the low deamination, mostly unmethylated CGIs.
(A) H3K9me2 nucleation sites (blue) are biased towards CGIs with low rates of C- > T deamination (green) as compared to CGIs that evolutionarily
show G/C gain (red). (B) The increase in chromatin accessibility is more dramatic at the CGIs with low rates of C- > T deamination (green) as com-
pared to CGIs that evolutionarily have G/C gain (red). (C) DNA methylation levels in CD34+ HSPCs for CGIs with low rates of C- > T deamination
(green) and CGIs displaying G/C gain (red) indicate that the CGIs with low rates of C- > deamination are mostly unmethylated while the GCIs dis-
playing evolutionary gain of G/C content are mostly methylated.
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ously [6].FAIRE-seq
FAIRE was performed as previously described [13]. Paired-
end sequencing (100 × 100) was performed in replicate on a
HiSeq 2500 to obtain ~50 M reads per replicate. Sequenced
reads were aligned to the hg19 build of the human genome
(hg19; GRCh37) using bowtie2 [20] with local read
alignment. Aligned reads were further filtered to ex-
clude improperly paired reads and duplicate reads.
Wiggle tracks were prepared for visualization on the
UCSC Genome Browser [15] by sliding 10 bp windows
across each chromosome and counting the sequenced
fragments overlapping each window; reproducibility of
FAIRE tracks was assessed visually and replicate libraries
were combined to make final bed files for each condition.
Peaks of FAIRE-seq were called with F-seq [21] using de-
fault parameters and a 200 bp feature length. Irreprodu-
cible Discover Rate analysis [22] was performed to identify
reproducible peaks.H3K9me2 ChIP-seq
Aligned bam files for H3K9me2 ChIP-seq data were
obtained from [6]. Wiggle tracks were generated for
visualization on the UCSC Genome Browser [15]. Visual
examination of CD34 HSPC H3K9me2 peaks indicated
punctate peaks and regions of enrichment were identified
using MACS with a P value threshold of 1 × 10-10. This
analysis resulted in 43,159 peaks.DNA methylation
DNA methylation results were obtained from [6].
Visualization of DNA methylation levels in CD90+
HSCs and CD34+ HSPCs (see Additional file 5: Figure S4)
revealed a bimodal distribution. CGIs were considered
methylated with a methylation score >0.75 and unmethy-
lated with a methylation score <0.25. All regions in be-
tween were considered indeterminate.H3K9me2 simulation
Simulation of random sites for Figure 2E was performed
by randomly choosing 1,000 regions of 1 kb 10,000
times and calculating the fold change of FAIRE signal
for UNC0638 over DMSO at each region.Data access
The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus [23] and are access-
ible through GEO Series accession number GSE59749.Additional files
Additional file 1: Table S1. FAIRE-seq statistics for UNC0638- and
DMSO-treated cells.
Additional file 2: Figure S1. qPCR validation of FAIRE-seq and ChIP-seq
results. H3K9me2 ChIP-seq and FARE-seq profiles for DMSO- and UNC0638-
treated cells at the (A) HOXA9 and (B) MLLT11 loci. Primer coordinates for
qPCR are indicated by green bars. (C) Corresponding qPCR results. Relative
values represent qPCR values normalized to GAPDH.
Additional file 3: Figure S2. FAIRE fold change for H3K9me2
nucleation sites as compared to the whole genome. The increase in
chromatin accessibility as measured by the log of the fold change of the
FAIRE signal for UNC0638 over DMSO for all H3K9me2 nucleation sites
(H3K9me2) as compared to the log of the fold change for FAIRE
(UNC0638/DMSO) for all 1 kb windows across the genome tiled in 50 bp
increments (Background).
Additional file 4: Figure S3. The FAIRE signals for UNC0638 and DMSO
for three classes of CGIs: (green) those with low rates of C- > T deamination
that are predicted to be mostly unmethylated, (red) those that display rapid
G/C gain that are predicted to be constitutively methylated, and (blue)
those under selection.
Additional file 5: Figure S4. DNA methylation distributions for probes
in (A) CD34+ DMSO and (B) CD90+ cells.
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